Tag Archives: SixPeaks Bio

Pfizer Wins Metsera Bidding War; Lilly Partners for RNAi Drug Discovery; AZ Acquires Obesity Start-Up; Tandem’s Mobi Cleared for Android Use; Merck, Amgen, AZ, Ionis Data at AHA 2025; November CHMP Agenda

A series of cardiometabolic-related news items have been observed from Metsera/Pfizer, Lilly, AstraZeneca, Tandem Diabetes Care, Merck, Amgen, Bayer, Ionis Pharmaceuticals, Camurus, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Zealand Ph2a Dapiglutide Results; SixPeaks Launches as Obesity Startup with AZ Investment; Medtronic CY Q1 ’24 Earnings; Scholar Rock and Sagimet Investor Days; CLEAR Outcomes EU Approval

A series of cardiometabolic-related news items have been observed from Zealand Pharma, SixPeaks Bio, Medtronic, Scholar Rock, Sagimet Biosciences, and Esperion Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here